CONTACT US: Contact info
|
Citation |
Das S, Prochaska JJ. Expert Rev. Respir. Med. 2017; 11(10): 841-850. |
|
Copyright |
(Copyright © 2017, Future Drugs) |
|
DOI |
|
PMID |
28756728 |
|
PMCID |
|
|
Abstract |
Tobacco remains the leading preventable cause of death in the US, accounting for over 520,000 deaths annually. While the smoking prevalence has declined over the past 50 years, those with mental illness and addictive disorders continue to smoke at high levels and with significant tobacco-related health problems. Areas covered: This review highlights the epidemiology, contributing factors, and evidence-base for intervening upon tobacco use in those with mental illness and addictive disorders. Historically underprioritized, a growing body of literature supports treating tobacco within mental health and addiction treatment settings. Critically, treating tobacco use appears to support, and not harm, mental health recovery and sobriety. This review also summarizes novel, emerging approaches to mitigate the harms of cigarette smoking. Expert commentary: People with mental illness and addictive disorders have a high prevalence of tobacco use with serious health harms. Treating tobacco use is essential. Evidence-based strategies include individual treatments that are stage-matched to readiness to quit and combine cessation medications with behavioral therapies, supported by smoke-free policies in treatment settings and residential environments. Emerging approaches, with a focus on harm reduction, are electronic nicotine delivery systems and tobacco regulatory efforts to reduce the nicotine content in cigarettes, thereby reducing their addiction potential. Language: en |
|
Keywords |
Humans; Substance-Related Disorders; Suicidal Ideation; dual diagnosis; mental illness; Smoking; Hotlines; smoking; Mental Disorders; nicotine; Tobacco; Psychotropic Drugs; nicotine replacement therapy; Nicotinic Agonists; substance use disorders; Tobacco Smoke Pollution; Cognitive Behavioral Therapy; Electronic Nicotine Delivery Systems; Substance Withdrawal Syndrome; Smoking Cessation; Tobacco Use Cessation Devices; Genome-Wide Association Study; Cytochrome P-450 CYP1A2; CYP1A2; e-cigarette; quit-line |